Place du Rituximab dans le traitement de la sclérose en plaques
| dc.contributor.advisor | N. KISSANI | |
| dc.contributor.author | Imane HAKIM | |
| dc.date.accessioned | 2023-09-19T14:15:24Z | |
| dc.date.accessioned | 2026-01-28T12:21:13Z | |
| dc.date.available | 2023-09-19T14:15:24Z | |
| dc.date.issued | 2022 | |
| dc.description.collaborator | M. CHRAA | |
| dc.description.collaborator | N. LOUHAB | |
| dc.identifier.uri | https://toubkal.imist.ma/handle/123456789/22033 | |
| dc.identifier.uri | https://doi.org/10.83129/toubkal-1547 | |
| dc.language.iso | fr | |
| dc.publisher | Faculté de Médecine et de Pharmacie, Marrakech | fr_FR |
| dc.publisher | Sciences médicales | fr_FR |
| dc.subject.other | Neurologie, Physiologie, Neurologie | |
| dc.subject.specific | Sclérose en plaques | |
| dc.subject.specific | Rituximab | |
| dc.subject.specific | Sévérité | |
| dc.title | Place du Rituximab dans le traitement de la sclérose en plaques | fr_FR |
Files
Original bundle
1 - 1 of 1